Background Cardiovascular disease (CVD) is a common comorbidity in type 2 diabetes
(T2DM). CVD's prevalence has been growing over time. Purpose To estimate the current …

Obesity must be considered a real pathology. In the world wide, obesity represent one of the
major public health issue associated with increased morbidity and mortality. Overweight or …

Aims To evaluate current evidence of glucagon-like peptide-1 receptor agonists (GLP-1RAs)
on blood pressure, heart rate, and hypertension in patients with type 2 diabetes. Methods …

Aims Aside from lowering blood glucose, glucagon‐like peptide‐1 receptor agonists (GLP‐1
RAs) attract much attention because of their cardioprotective effects. The aim of this study …

Macrovascular and microvascular complications that accompany Type 2 diabetes mellitus
(T2DM) add to the burden among patients. The purpose of this systematic review is to …

Background The majority of patients with type 2 diabetes mellitus have blood pressure (BP)
exceeding the recommended value of< 130/80mmHg. Optimal control of hyperglycemia and …

Abstract Glucagon-like peptide 1 (GLP-1) is an incretin hormone responsible for
amplification of insulin secretion when nutrients are given orally, as opposed to …

Introduction Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in
people with type 2 diabetes mellitus (T2DM). The objectives of this systematic literature …

Cardiovascular and related metabolic diseases are significant global health challenges.
Glucagon-like peptide 1 (GLP-1) is a brain-gut peptide secreted by the ileal endocrine …

Resumen DOMINGUEZ SANCHEZ-MIGALLON, Pedro y GRUPO AZUER. Control
Metabólico en Pacientes Diabéticos Tipo 2: grado de Control y nivel de Conocimientos …